Head to head
Eloralintide against Cagrilintide
Two amylin agonists in phase 3 from different sponsors. Eloralintide is described as selective for the amylin receptor, which is the mechanistic claim that separates them, and no trial has compared the two.
Column A
EloralintideEloralintide (LY3841136)
Lilly's selective amylin agonist that reached about 20% weight loss in Phase 2 with milder gut side effects than GLP-1 drugs, now in Phase 3 alone and as an add-on to tirzepatide.
Column B
CagrilintideCagrilintide (long-acting amylin receptor agonist)
An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.
Side by side, on the facts we can check
| Attribute | Eloralintide | Cagrilintide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational; Phase 3 (ENLIGHTEN program) | Investigational, not FDA-approved |
| Half-life | Weekly dosing (long-acting) | ~7 days |
| Molecular weight | 4,526 Da | ~3,700 Da |
| Mechanism | Activates amylin receptors (calcitonin receptor plus RAMP complexes), slowing gastric emptying and reducing appetite through a pathway that is independent of GLP-1. | Agonizes amylin receptors in the hypothalamus and brainstem to promote satiety and delay gastric emptying, complementing GLP-1 signaling. |
| Human studies cited | 3 | 3 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Eloralintide and Cagrilintide?
Eloralintide: Lilly's selective amylin agonist that reached about 20% weight loss in Phase 2 with milder gut side effects than GLP-1 drugs, now in Phase 3 alone and as an add-on to tirzepatide. Cagrilintide: An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.
Which has stronger research evidence, Eloralintide or Cagrilintide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Eloralintide profile were human work, against 3 of 3 for Cagrilintide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Eloralintide and Cagrilintide FDA-approved?
Eloralintide: Investigational; Phase 3 (ENLIGHTEN program). Cagrilintide: Investigational, not FDA-approved.
Related posts
Blog articles that cover Eloralintide or Cagrilintide, newest first.
- Metabolic / Sep 8, 2026 / 9 minCagrilintide: The Amylin Half of CagriSema, and Why People Search 'Cagrilintide with Retatrutide'
- Metabolic / Sep 8, 2026 / 9 minRetatrutide vs Tirzepatide vs Semaglutide vs the Pill: The 2026 GLP-1 Field Guide
- Research / Sep 8, 2026 / 11 minNew Peptides and Longevity Compounds in 2026: What Is Actually New, What Is Newly Legal, and What Is Just New to Vendors
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.